BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17445778)

  • 21. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
    Gessa GL; Casu MA; Carta G; Mascia MS
    Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesenteric vasodilation mediated by endothelial anandamide receptors.
    Wagner JA; Varga K; Járai Z; Kunos G
    Hypertension; 1999 Jan; 33(1 Pt 2):429-34. PubMed ID: 9931142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
    Giuffrida A; Beltramo M; Piomelli D
    J Pharmacol Exp Ther; 2001 Jul; 298(1):7-14. PubMed ID: 11408519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ; Brunk LK; Selley DE
    Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens.
    Pertwee RG; Griffin G; Lainton JA; Huffman JW
    Eur J Pharmacol; 1995 Sep; 284(3):241-7. PubMed ID: 8666005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds.
    Sugiura T; Kodaka T; Nakane S; Miyashita T; Kondo S; Suhara Y; Takayama H; Waku K; Seki C; Baba N; Ishima Y
    J Biol Chem; 1999 Jan; 274(5):2794-801. PubMed ID: 9915812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
    FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha(2(-)) and CB(1) receptors: similarities to presynaptic imidazoline and edg receptors.
    Molderings GJ; Bönisch H; Hammermann R; Göthert M; Brüss M
    Neurochem Int; 2002 Feb; 40(2):157-67. PubMed ID: 11738482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.
    Wallace MJ; Wiley JL; Martin BR; DeLorenzo RJ
    Eur J Pharmacol; 2001 Sep; 428(1):51-7. PubMed ID: 11779037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
    Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoid modulation of intestinal propulsion in mice.
    Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
    Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons.
    Twitchell W; Brown S; Mackie K
    J Neurophysiol; 1997 Jul; 78(1):43-50. PubMed ID: 9242259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study.
    Ferraro L; Tomasini MC; Gessa GL; Bebe BW; Tanganelli S; Antonelli T
    Cereb Cortex; 2001 Aug; 11(8):728-33. PubMed ID: 11459762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
    Acquas E; Pisanu A; Marrocu P; Di Chiara G
    Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture.
    Kim D; Thayer SA
    J Neurosci; 2001 May; 21(10):RC146. PubMed ID: 11319244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.
    Mato S; Pazos A; Valdizán EM
    Eur J Pharmacol; 2002 May; 443(1-3):43-6. PubMed ID: 12044790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
    Landi M; Croci T; Rinaldi-Carmona M; Maffrand JP; Le Fur G; Manara L
    Eur J Pharmacol; 2002 Aug; 450(1):77-83. PubMed ID: 12176112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Internalization and recycling of the CB1 cannabinoid receptor.
    Hsieh C; Brown S; Derleth C; Mackie K
    J Neurochem; 1999 Aug; 73(2):493-501. PubMed ID: 10428044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.
    Wilson RI; Nicoll RA
    Nature; 2001 Mar; 410(6828):588-92. PubMed ID: 11279497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.